Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt 2017 SR
The report details Gedeon Richter's economic, environmental, and social performance for the 2016-2017 period. Key highlights include the launch of the company's first biosimilar product and the antipsychotic drug Vraylar. The company transitioned to reporting in accordance with GRI Standards and conducted a group-level materiality assessment involving 17 international sites. Significant investments were made in biotechnology, specifically the expansion of the Debrecen plant. The report also highlights the 'Richter Health City' program and various initiatives supporting women's health and education.
Company: Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
Sector: Manufacturing
Country: Hungary
Year: 2017
Type: SR
Pages: 43
Back to company
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
Sustainability Report
The report details Gedeon Richter's economic, environmental, and social performance for the 2016-2017 period. Key highlights include the launch of the company's first biosimilar product and the antipsychotic drug Vraylar. The company transitioned to reporting in accordance with GRI Standards and conducted a group-level materiality assessment involving 17 international sites. Significant investments were made in biotechnology, specifically the expansion of the Debrecen plant. The report also highlights the 'Richter Health City' program and various initiatives supporting women's health and education.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2016 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees